keyword
Keywords Autologous stem cell transplan...

Autologous stem cell transplant amyloidosis

https://read.qxmd.com/read/36652193/diagnosis-and-treatment-of-al-amyloidosis
#21
REVIEW
Giovanni Palladini, Paolo Milani
Systemic light chain (AL) amyloidosis is caused by an usually small B cell clone that produces a toxic light chain forming amyloid deposits in tissue. The heart and kidney are the major organs affected, but all others, with the exception of the CNS, can be involved. The disease is rapidly progressive, and it is still diagnosed late. Screening programs in patients followed by hematologists for plasma cell dyscrasias should be considered. The diagnosis requires demonstration in a tissue biopsy of amyloid deposits formed by immunoglobulin light chains...
February 2023: Drugs
https://read.qxmd.com/read/36574171/a-comprehensive-overview-of-al-amyloidosis-disease-characteristics-accumulated-over-two-decades-at-a-single-referral-center-in-korea
#22
REVIEW
Sang Eun Yoon, Darae Kim, Jin-Oh Choi, Ju-Hong Min, Byoung Joon Kim, Jung-Sun Kim, Jung Eun Lee, Joon Young Choi, Eun-Seok Jeon, Seok Jin Kim, Kihyun Kim
BACKGROUND: Characteristics of AL amyloidosis across Asia are not well-described in the literature. Thus, we overviewed the incidence and disease characteristics of AL amyloidosis in Korea. METHODS: We collected medical records of 302 AL amyloidosis patients and compared survival outcomes by predominant treatment strategy and at four time points: 1995-2003, 2004-2008, 2009-2013, and 2014-2018. RESULTS: The median age was 62 years (36-83)...
May 2023: International Journal of Hematology
https://read.qxmd.com/read/36533960/the-impact-of-post-transplant-doxycycline-in-al-amyloidosis-updated-results-after-long-term-follow-up
#23
JOURNAL ARTICLE
Nadine Abdallah, Angela Dispenzieri, Eli Muchtar, Francis K Buadi, Prashant Kapoor, Martha Q Lacy, Yi L Hwa, Amie Fonder, Miriam A Hobbs, Suzanne R Hayman, Nelson Leung, David Dingli, Ronald S Go, Yi Lin, Wilson I Gonsalves, Moritz Binder, Taxiarchis Kourelis, Rahma Warsame, Robert A Kyle, S Vincent Rajkumar, Morie A Gertz, Shaji K Kumar
INTRODUCTION: The current treatment paradigm of AL amyloidosis lacks effective fibril-directed therapies. Doxycycline has been shown to have anti-fibril properties in preclinical models. In 2012, we reported that posttransplant prophylaxis with doxycycline was associated with improved survival compared to penicillin in patients with haematologic response. We provide here updated results after long-term follow up. METHODS: We included 553 patients who underwent transplant between July 24th , 1996, and June 24th , 2014...
December 19, 2022: Amyloid: the International Journal of Experimental and Clinical Investigation
https://read.qxmd.com/read/36464620/single-center-experience-of-autologous-stem-cell-transplantation-in-patients-with-systemic-light-chain-amyloidosis-in-korea
#24
JOURNAL ARTICLE
Hye Ryeon Kim, Sang Eun Yoon, Darae Kim, Jin-Oh Choi, Ju-Hong Min, Byung Jun Kim, Jung Sun Kim, Jung Eun Lee, Joon Young Choi, Eun-Seok Jeon, Seok Jin Kim, Kihyun Kim
BACKGROUND: Systemic light chains is the most common systemic amyloidosis. In patients with AL amyloidosis, the prognosis is influenced by the extent of organ damage, especially cardiac involvement. Autologous stem cell transplantation (ASCT) is a highly effective treatment for AL amyloidosis for selective patient METHODS: One hundred patients treated with ASCT for AL amyloidosis were reviewed in the Samsung Medical Center amyloidosis cohort. The cardiac, renal, and hematologic response was analyzed, and survival results compared based on organ involvement and hematologic response...
October 22, 2022: Clinical Lymphoma, Myeloma & Leukemia
https://read.qxmd.com/read/36444232/al-amyloidosis-for-cardiologists-awareness-diagnosis-and-future-prospects-jacc-cardiooncology-state-of-the-art-review
#25
REVIEW
Ashutosh D Wechalekar, Marianna Fontana, C Cristina Quarta, Michaela Liedtke
Amyloid light chain (AL) amyloidosis is a rare, debilitating, often fatal disease. Symptoms of cardiomyopathy are common presenting features, and patients often are referred to cardiologists. Cardiac amyloid infiltration is the leading predictor of death. However, the variable presentation and perceived rarity of the disease frequently lead to delay in suspecting amyloidosis as a cause of heart failure, leading to misdiagnoses and a marked delay in diagnosis, with devastating consequences for the patient. A median time from symptom onset to correct diagnosis of about 2 years is often too long when median survival from diagnosis for patients with AL amyloidosis and cardiomyopathy is 4 months to 2 years...
November 2022: JACC CardioOncology
https://read.qxmd.com/read/36381809/light-chain-amyloidosis-presenting-as-a-septic-shock-a-case-report-and-review-of-literature
#26
Talal Bazzi, Kory Kropman, Mark Benjamin, Ali Al-Rammahi
Light chain (AL) amyloidosis is a plasma cell dyscrasia that results in an overproduction of immunoglobulins of the lambda or kappa light chains. These monoclonal ALs begin to form fibrils with each other and exert their toxic effect by depositing in different organs around the body. Disease presentation is indistinct, but it is ideal to diagnose this disorder before end-organ damage is caused. Once the diagnosis of AL amyloidosis is confirmed, the best treatment is autologous stem cell transplantation once a candidate is deemed fit for it; however, there are other chemotherapy agents whose patients can be administered until they undergo stem cell transplantation...
October 2022: Curēus
https://read.qxmd.com/read/36323398/characteristics-of-engraftment-syndrome-following-autologous-stem-cell-transplantation-in-light-chain-amyloidosis-with-renal-involvement
#27
JOURNAL ARTICLE
Fujia Miao, Guisheng Ren, Jinzhou Guo, Liang Zhao, Weiwei Xu, Xianghua Huang
Engraftment syndrome (ES) is a clinical complication that occurs during the neutrophil recovery phase following hematopoietic stem cell transplantation. The clinical features of ES in light chain (AL) amyloidosis remains to be thoroughly investigated. This study was conducted to better understand the characteristics of ES following autologous stem cell transplantation (ASCT) in AL amyloidosis with renal involvement. We conducted this single-center retrospective study in 302 patients with AL amyloidosis who underwent ASCT between July 2010 and December 2021...
February 2023: Transplantation and cellular therapy
https://read.qxmd.com/read/36206073/treatment-of-amyloid-light-chain-cardiac-amyloidosis-systematic-review-and-future-directions
#28
REVIEW
Dunya Alsomali, Dania Mohty, Martha Grogan, Angela Dispenzieri, Mahmoud Aljurf, Shaji Kumar, Morie A Gertz, Amr Hanbali, Shahrukh K Hashmi
BACKGROUND: Several treatment strategies for amyloid light chain cardiac amyloidosis (AL-CA) have been described in the literature; however, there is no consensus about the optimal approach to AL-CA. OBJECTIVE: We conducted this systematic review to summarize current evidence from published studies about the safety and efficacy of various treatment regimens for patients with AL-CA, mainly focusing on autologous stem cell transplant (ASCT) and heart transplant. METHODS: An electronic literature search of PubMed, Web of Science, Scopus, EBSCO, and CINAHL Plus was conducted through December 2019 using the relevant keywords and prespecified MeSH terminology...
October 2022: Clinical Advances in Hematology & Oncology: H&O
https://read.qxmd.com/read/36164164/mm-315-light-chain-amyloidosis-patients-treated-with-daratumumab-a-single-center-experience
#29
JOURNAL ARTICLE
Lucrecia Oses, Erika Brulc, Marcelina Carretero, Elsa Nucifora
BACKGROUND: Light chain (AL) amyloidosis is an extreme form of systemic amyloidosis, causing organ dysfunction, mainly affecting the heart and kidneys. Daratumumab was the first monoclonal CD38 antibody approved for the treatment of AL amyloidosis. There are few real-world data about the use of daratumumab in patients with AL amyloidosis from Latin America. OBJECTIVE: Describe the hematological and organ response in patients with AL amyloidosis treated with daratumumab...
October 2022: Clinical Lymphoma, Myeloma & Leukemia
https://read.qxmd.com/read/36054582/clinical-features-and-outcomes-of-renal-amyloidosis-in-hong-kong
#30
JOURNAL ARTICLE
Ronald Chi Chun Lin, Sze Kit Yuen, Siu Fai Cheung, Hon Lok Tang, Samuel Ka Shun Fung
AIM: Early symptoms of primary (AL) amyloidosis are non-specific. Any delay in diagnosis and treatment results in poor outcome despite increasing treatment options. We aimed to determine baseline risk factors that identify patients with poor kidney outcomes and overall survivals. METHODS: We recruited all patients aged 18 years or above with biopsy-proven renal amyloidosis between years 2000 and 2019 in three Hong Kong regional hospitals. Patients' clinical and pathological parameters, treatment response, kidney outcomes and overall survivals were recorded and analysed...
November 2022: Nephrology
https://read.qxmd.com/read/36039749/recent-guidelines-for-high-dose-chemotherapy-and-autologous-stem-cell-transplant-for-systemic-al-amyloidosis-a-practitioner-s-perspective
#31
REVIEW
Joshua Bomsztyk, Jahanzaib Khwaja, Ashutosh D Wechalekar
INTRODUCTION: High-dose melphalan followed by autologous stem cell transplant (ASCT) has been transformative in treating AL amyloidosis since the early nineties. Recently, the European Hematology Association (EHA) and International Society of Amyloidosis (ISA) have developed a combined guideline for the management of patients undergoing an ASCT for AL amyloidosis. AREAS COVERED: In this practitioner's perspective, we review the guideline, focusing on 6 major areas and offer practical advice for its application...
September 2022: Expert Review of Hematology
https://read.qxmd.com/read/35987926/impact-of-the-changing-landscape-of-induction-therapy-prior-to-autologous-stem-cell-transplantation-in-540-newly-diagnosed-myeloma-patients-a-retrospective-real-world-study
#32
JOURNAL ARTICLE
Song-Yau Wang, Tanja Holzhey, Simone Heyn, Thomas Zehrfeld, Susann Fricke, Franz Albert Hoffmann, Cornelia Becker, Leanthe Braunert, Thomas Edelmann, Inessa Paulenz, Marcus Hitzschke, Franziska Flade, Andreas Schwarzer, Klaus Fenchel, Georg-Nikolaus Franke, Vladan Vucinic, Madlen Jentzsch, Sebastian Schwind, Saskia Hell, Donata Backhaus, Thoralf Lange, Dietger Niederwieser, Markus Scholz, Uwe Platzbecker, Wolfram Pönisch
INTRODUCTION: Autologous stem cell transplantation (ASCT) is the standard treatment for younger patients with newly diagnosed multiple myeloma (MM). However, due to restrictive exclusion criteria, more than half of eligible patients are usually excluded from transplant studies. METHODS: This retrospective monocentric analysis included 540 patients with MM who received an ASCT between 1996 and 2019. RESULTS: Up to 2005, induction therapy consisted mainly of conventional chemotherapies, e...
August 20, 2022: Journal of Cancer Research and Clinical Oncology
https://read.qxmd.com/read/35970300/modified-high-dose-versus-high-dose-melphalan-conditioning-in-older-patients-undergoing-autologous-stem-cell-transplantation-for-immunoglobulin-light-chain-amyloidosis
#33
JOURNAL ARTICLE
Hamza Hassan, Karina Verma, Grace Ferri, Dina Brauneis, Karen Quillen, J Mark Sloan, Vaishali Sanchorawala, Camille Vanessa Edwards
High dose melphalan and autologous stem cell transplant (HDM/SCT) induces deep hematologic responses (HR) in patients with newly diagnosed systemic immunoglobulin light chain (AL) amyloidosis. Modifying melphalan conditioning dose (mHDM <140 mg/m2 ) is considered in older patients due to concerns regarding tolerability. Age does not predict frailty and dose modification could compromise responses in an era where effective non-transplant regimens are available. We analyzed 43 patients ≥ 65 years with AL amyloidosis who underwent SCT at Boston University Amyloidosis Center between 2011 and 2020...
August 12, 2022: Transplantation and cellular therapy
https://read.qxmd.com/read/35943427/advances-in-the-treatment-of-light-chain-amyloidosis
#34
REVIEW
Giovanni Palladini, Paolo Milani
PURPOSE OF REVIEW: After many years, the management of systemic light chain (AL) amyloidosis is entering the era of evidence-based medicine, with three recently published randomized clinical trials, a regimen (daratumumab, cyclophosphamide, bortezomib, and dexamethasone, daratumumab-CyBorD) labeled for upfront therapy, more clinical trials ongoing, and published guidelines. In this review, we discuss how current practice is changing based on this data. RECENT FINDINGS: Daratumumab-CyBorD grants unprecedentedly high rates of hematologic and organ response and became the novel standard-of-care in AL amyloidosis...
November 1, 2022: Current Opinion in Oncology
https://read.qxmd.com/read/35904916/-recommendations-for-the-treatment-of-al-amyloidosis
#35
JOURNAL ARTICLE
Erika B Brulc, Marcelina Carretero, María A Aguirre, Agustina Negro, María D Ulacia, Diego Perez de Arenaza, Eugenia Villanueva, María S Sáez, Patricia Sorroche, María L Posadas Martínez, Elsa M Nucifora
INTRODUCTION: Immunoglobulin light chain (AL) amyloidosis is a rare disease. Treatment is challenging, justified in part by systemic compromise and limited scientific evidence. OBJECTIVES: Develop evidencebased recommendations that allow adequate treatment of patients with amyloidosis AL. METHODS: A list of PICO format questions focused on the effectiveness and safety of amyloidosis AL treatment was generated. PubMed, Cochrane and Epistemonikos were searched...
2022: Medicina
https://read.qxmd.com/read/35898379/bilateral-orbital-plasmacytomas-with-orbital-compartment-syndrome
#36
Rachel E Pyon, Grace C Wang, Yan Chu, Sunil Tulpule
Orbital plasmacytomas are uncommon soft-tissue plasma cell neoplasms that are associated with a monoclonal or myeloma protein. There are four types of plasma cell neoplasms: multiple myeloma (MM), monoclonal gammopathy of undetermined significance (MGUS), amyloidosis, and plasmacytoma. Plasmacytomas may be classified as medullary, occurring only within the bone, or extramedullary, occurring in soft tissues. Orbital plasmacytomas are extramedullary manifestations associated with MM and they may present with signs and symptoms such as unilateral proptosis, conjunctival injection, ocular pain, diplopia, and vision changes...
June 2022: Curēus
https://read.qxmd.com/read/35844314/hemophagocytic-syndrome-associated-intravascular-large-b-cell-lymphoma-with-dialysis-dependent-end-stage-renal-disease-treated-with-autologous-stem-cell-transplantation-using-a-modified-team-regimen
#37
Kudret Kama, Paul La Rosée, David Czock, Jan Bosch-Schips, Gerald Illerhaus
Due to the low incidence and the large number of postmortem diagnoses, treatment recommendations for intravascular large B-cell lymphoma (IVLBCL) are largely based on retrospective studies and case reports. There is little data on autologous stem cell transplantation (ASCT) in dialysis-dependent patients and choosing an adequate regimen and dosing is difficult. Here, we report the treatment of a patient with relapsed IVLBCL and end-stage renal disease caused by lymphoma-associated renal AA amyloidosis using a modified TEAM (thiotepa, etoposide, cytarabine, and melphalan) regimen and ASCT...
June 2022: Curēus
https://read.qxmd.com/read/35817492/macroglossia-as-the-initial-presentation-of-al-amyloidosis-review-and-updates-in-treatment
#38
JOURNAL ARTICLE
Adriani Samuel Cherico, Ali Rizvi, Thejus Jayakrishnan, Prerna Mewawalla
We encountered a man in his 60s presenting with worsening macroglossia. The patient underwent extensive otolaryngology evaluation and was diagnosed with primary (AL) amyloidosis on tongue biopsy with Congo red stain. The patient then underwent a bone marrow biopsy and was also found to have concurrent multiple myeloma. He started induction therapy with daratumumab and CyBorD (cyclophosphamide, bortezomib, dexamethasone). Cardiac MRI revealed extensive cardiac amyloidosis and the patient was deemed high risk for autologous stem cell transplant (auto-HCT)...
July 11, 2022: BMJ Case Reports
https://read.qxmd.com/read/35747578/the-clinical-characteristics-and-prognosis-of-chinese-patients-with-light-chain-amyloidosis-a-retrospective-multicenter-analysis
#39
JOURNAL ARTICLE
Donghua He, Fangshu Guan, Minli Hu, Gaofeng Zheng, Jingsong He, Xiaoyan Han, Yang Yang, Pan Hong, Gang Wang, Yi Zhao, Wenjun Wu, Zhen Cai
To retrospectively identify the critical characteristics and prognostic factors of light-chain amyloidosis. PATIENTS AND METHODS: Data were collected and compared from 91 patients who were diagnosed with light-chain amyloidosis at four hospitals between January 2010 and November 2018. We analyzed the clinical characteristics and performed an overall survival (OS) analysis. RESULTS: Patients (median age, 60 years) were diagnosed with organ involvement of the kidney (91...
July 2022: Indian Journal of Hematology & Blood Transfusion
https://read.qxmd.com/read/35680633/-a-clinical-retrospective-analysis-of-newly-diagnosed-multiple-myeloma-patients-with-systemic-light-chain-amyloidosis
#40
JOURNAL ARTICLE
Y Liu, H Y You, L Z Yan, S Jin, J J Shang, X L Shi, S Yan, W Q Yao, D P Wu, W Liu, C C Fu
Objective: To analyze the clinical characteristics, treatment response, and prognosis of newly diagnosed symptomatic multiple myeloma (MM) patients with systemic light chain amyloidosis (AL) . Methods: The clinical data of 160 patients with newly diagnosed MM treated at the First Affiliated Hospital of Soochow University from January 1, 2017 to October 31, 2018, were retrospectively analyzed. According to the histopathological biopsy results of bone marrow, skin, and other tissues, the patients were divided into two groups according to whether amyloidosis was combined or not, namely, the MM+AL group and the MM group...
April 14, 2022: Zhonghua Xue Ye Xue za Zhi, Zhonghua Xueyexue Zazhi
keyword
keyword
29001
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.